Voloridge Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.8M | Buy |
+201,257
| New | +$44.6M | 0.18% | 161 |
|
|
2025
Q4 | – | Sell |
-397,195
| Closed | -$92M | – | 1111 |
|
|
2025
Q3 | $92M | Sell |
397,195
-809,539
| -67% | -$165M | 0.31% | 82 |
|
|
2025
Q2 | $224M | Buy |
1,206,734
+1,068,140
| +771% | +$199M | 0.83% | 10 |
|
|
2025
Q1 | $29M | Buy |
+138,594
| New | +$26.9M | 0.11% | 259 |
|
|
2024
Q1 | – | Sell |
-567,486
| Closed | -$87.9M | – | 1119 |
|
|
2023
Q4 | $87.9M | Buy |
567,486
+196,150
| +53% | +$28.6M | 0.35% | 77 |
|
|
2023
Q3 | $55.4M | Sell |
371,336
-829,561
| -69% | -$122M | 0.27% | 93 |
|
|
2023
Q2 | $162M | Buy |
+1,200,897
| New | +$176M | 0.76% | 8 |
|
|
2023
Q1 | – | Sell |
-54,862
| Closed | -$8.87M | – | 1332 |
|
|
2022
Q4 | $8.87M | Sell |
54,862
-276,979
| -83% | -$42.5M | 0.05% | 465 |
|
|
2022
Q3 | $44.5M | Buy |
331,841
+214,813
| +184% | +$30.8M | 0.24% | 107 |
|
|
2022
Q2 | $17.9M | Sell |
117,028
-189,217
| -62% | -$28.9M | 0.09% | 293 |
|
|
2022
Q1 | $49.6M | Buy |
306,245
+187,169
| +157% | +$27.2M | 0.28% | 80 |
|
|
2021
Q4 | $16.1M | Buy |
119,076
+95,208
| +399% | +$11.2M | 0.09% | 323 |
|
|
2021
Q3 | $2.58M | Sell |
23,868
-2,509
| -10% | -$287K | 0.02% | 961 |
|
|
2021
Q2 | $2.97M | Buy |
+26,377
| New | +$2.97M | 0.02% | 836 |
|
|
2020
Q4 | – | Sell |
-273,751
| Closed | -$24M | – | 1280 |
|
|
2020
Q3 | $24M | Buy |
+273,751
| New | +$25.8M | 0.2% | 123 |
|
|
2020
Q2 | – | Sell |
-159,158
| Closed | -$12.1M | – | 1222 |
|
|
2020
Q1 | $12.1M | Sell |
159,158
-137,243
| -46% | -$11.7M | 0.35% | 59 |
|
|
2019
Q4 | $26.2M | Sell |
296,401
-29,148
| -9% | -$2.42M | 0.51% | 26 |
|
|
2019
Q3 | $24.7M | Buy |
+325,549
| New | +$22.3M | 0.43% | 28 |
|
|
2019
Q2 | – | Sell |
-351,171
| Closed | -$28.3M | – | 724 |
|
|
2019
Q1 | $28.3M | Buy |
+351,171
| New | +$28.7M | 0.85% | 18 |
|
|
2018
Q4 | – | Sell |
-430,636
| Closed | -$40.7M | – | 396 |
|
|
2018
Q3 | $40.7M | Buy |
430,636
+247,930
| +136% | +$23.5M | 0.89% | 29 |
|
|
2018
Q2 | $16.9M | Sell |
182,706
-422,882
| -70% | -$41.3M | 0.45% | 52 |
|
|
2018
Q1 | $57.3M | Buy |
+605,588
| New | +$66.5M | 1.35% | 11 |
|
|
2017
Q2 | – | Sell |
-16,912
| Closed | -$1.1M | – | 390 |
|
|
2017
Q1 | $1.1M | Buy |
+16,912
| New | +$1.06M | 0.03% | 378 |
|
|
2016
Q2 | – | Sell |
-231,054
| Closed | -$13.2M | – | 280 |
|
|
2016
Q1 | $13.2M | Buy |
+231,054
| New | +$12.9M | 0.31% | 71 |
|
|
2015
Q4 | – | Sell |
-87,019
| Closed | -$4.74M | – | 173 |
|
|
2015
Q3 | $4.74M | Buy |
+87,019
| New | +$5.66M | 0.22% | 113 |
|
|
2014
Q3 | – | Sell |
-132,244
| Closed | -$7.46M | – | 96 |
|
|
2014
Q2 | $7.46M | Buy |
+132,244
| New | +$6.94M | 0.71% | 31 |
|
Other funds holding ABBV
VCM
VPM
Voloridge Investment Management's ABBV Position: Q1 2026 in Review
Voloridge Investment Management opened a new position in AbbVie (ABBV) in Q1 2026: 201,257 shares worth $43.8M. The stake represents 0.18% of the portfolio and ranks #161 among its holdings. This is a return to the name: Voloridge Investment Management previously reported a position in ABBV as recently as Q3 2025.
Voloridge Investment Management first reported a position in ABBV in Q2 2014 and has held it in 26 quarters since. The position peaked at $224M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Voloridge Investment Management held 201,257 shares of AbbVie worth $43.8M as of Q1 2026.
- AbbVie was a new Voloridge Investment Management position in Q1 2026.
- AbbVie made up 0.18% of Voloridge Investment Management's portfolio in Q1 2026, its #161 holding.
- Voloridge Investment Management first reported a position in AbbVie in Q2 2014 and has held it in 26 quarters since.
- Voloridge Investment Management's AbbVie position peaked at $224M in Q2 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.